What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

1. Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard.BMJ open respiratory research · 2025
   Observational
2. Therapy ofMicroorganisms · 2024
   Review
3. Immunopathology of lung transplantation: from infection to rejection and vice versa.Frontiers in immunology · 2024
   Review
4. MarR-Dependent Transcriptional Regulation ofAntimicrobial agents and chemotherapy · 2023
   Article
5. Role of bacteriophage therapy for resistant infections in transplant recipients.Current opinion in organ transplantation · 2022
   Review
6. Same Game, Different Players: Emerging Pathogens of the CF Lung.mBio · 2021
   Review
7. Management and prophylaxis of bacterial and mycobacterial infections among lung transplant recipients.Annals of translational medicine · 2020
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 3 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as